Quick Answer
Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to native GLP-1, modified for extended half-life via albumin binding.
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with modifications at position 8 (Aib substitution) and position 34 (C-18 fatty diacid acylation). These modifications enable albumin binding, extending the half-life to approximately 7 days in research models. Upon binding GLP-1R, it activates the Gs → adenylyl cyclase → cAMP → PKA cascade, enhancing glucose-dependent insulin secretion, suppressing glucagon, and modulating hypothalamic appetite circuits. Semaglutide is the reference standard for GLP-1R pharmacology research.
Related Research Articles
More FAQs
BPC-157 is a synthetic 15-amino acid peptide fragment derived from human gastric juice protein, studied for tissue repair via VEGF upregulation and nitric oxide modulation.
How do peptides work?Peptides are short chains of amino acids that bind specific receptors to trigger intracellular signaling cascades, modulating biological processes at the molecular level.
What is Tirzepatide?Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first compound to simultaneously target both incretin receptors for synergistic metabolic research.
How should research peptides be stored?Lyophilized peptides should be stored at -20°C. Reconstituted peptides should be stored at 2–8°C and used within the specified stability window.
What does peptide purity mean?Peptide purity refers to the percentage of the target compound in the sample, measured by HPLC. Research-grade peptides are typically ≥98% pure.
Related Research & Documentation
